Acadia Pharmaceuticals (ACAD +10.6%) jumps after announcing an $86.4M private placement. The...
Acadia Pharmaceuticals (ACAD +10.6%) jumps after announcing an $86.4M private placement. The securities are to be sold at $4.43 per share, and will be used primarily to support completion of it's Phase III pimavanserin program, including a planned confirmatory Phase III pivotal trial in Parkinson's disease psychosis.
From other sites
at Nasdaq.com (Fri, 10:51AM)
at 4-traders.com (Mon, 8:03AM)
at Zacks.com (Mar 13, 2015)
at MarketWatch.com (Mar 11, 2015)
at CNBC.com (Mar 11, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs